Cited by 168Parkinson's Disease Mechanisms and TreatmentsMedicinal Plants and NeuroprotectionAlzheimer's disease research and treatments

Anti-Parkinsonian effects of Bacopa monnieri: Insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson’s disease

Jadiya, Pooja, Khan, Asif, Sammi, Shreesh Raj, Kaur, Supinder, Mir, Snober S., Nazir, Aamir·2011·Biochemical and Biophysical Research Communications

Abstract

Neurodegenerative Parkinson's disease (PD) is associated with aggregation of protein alpha synuclein and selective death of dopaminergic neurons, thereby leading to cognitive and motor impairment in patients. The disease has no complete cure yet; the current therapeutic strategies involve prescription of dopamine agonist drugs which turn ineffective after prolonged use. The present study utilized the powerful genetics of model system Caenorhabditis elegans towards exploring the anti-Parkinsonian effects of a neuro-protective botanical Bacopa monnieri. Two different strains of C. elegans; a transgenic model expressing "human" alpha synuclein [NL5901 (P(unc-54)::alphasynuclein::YFP+unc-119)], and a pharmacological model expressing green fluorescent protein (GFP) specifically in the dopaminergic neurons [BZ555 (P(dat-1)::GFP)] treated with selective catecholaminergic neurotoxin 6-hydroxy dopamine (6-OHDA), were employed for the study. B. monnieri was chosen for its known neuroprotective and cognition enhancing effects. The study examined the effect of the botanical, on aggregation of alpha synuclein, degeneration of dopaminergic neurons, content of lipids and longevity of the nematodes. Our studies show that B. monnieri reduces alpha synuclein aggregation, prevents dopaminergic neurodegeneration and restores the lipid content in nematodes, thereby proving its potential as a possible anti-Parkinsonian agent. These findings encourage further investigations on the botanical, and its active constituent compounds, as possible therapeutic intervention against Parkinson's disease.

Integrity signals

Registry

Crossref · 10.1016/j.bbrc.2011.09.010

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies have elucidated evidence for the role of Bacopa monnieri in epilepsy, dementia, and Parkinson's disease attenuation.

    “There have been studies that have elucidated evidence for the role of B. monnieri in epilepsy, dementia, and Parkinson’s disease attenuation [96,97].”

Cites

Flagged first, then by citations

1 of the 40 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Jadiya, P., Khan, A., Sammi, S. R., Kaur, S., Mir, S. S., & Nazir, A.
Affiliations
  • Central Drug Research Institute (IN)
  • Integral University (IN)
Corresponding author
Nazir, Aamir
Venue
Biochemical and Biophysical Research Communications
Publisher
Elsevier BV
Published
2011-10
Volume
413
Issue
4
Pages
605-610
ISSN
0006-291X (ISSN-L)
OpenAlex
W2053230417
Cited by
168
References
40
Citations by year
2026: 5 · 2025: 9 · 2024: 11 · 2023: 20 · 2022: 21 · 2021: 15 · 2020: 10 · 2019: 19 · 2018: 8 · 2017: 10 · 2016: 13 · 2015: 5 · 2014: 11 · 2013: 8 · 2012: 1
FWCI
4.26
Type
journal article
Language
en
Open access
closed
Locations
  • Biochemical and Biophysical Research Communications (publishedVersion)
  • PubMed (publishedVersion)
Funders
NIH National Center for Research Resources (NCRR)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Bacopa monnieri, Parkinson's disease, alpha-synuclein aggregation, dopaminergic neuron loss, neuroprotection, Caenorhabditis elegans, transgenic models, lipid content, longevity, dopamine agonist resistance
MeSH terms
Animals, Antiparkinson Agents, Disease Models, Animal, Longevity, Parkinson Disease, Plant Extracts, Caenorhabditis elegans, Neuroprotective Agents, Cytoprotection, Animals, Genetically Modified, Bacopa, alpha-Synuclein, Dopaminergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review